METIS TECHBIO-P (07666) has been included in the Hang Seng Composite Index, effective September 7.
Jitai Technology-P (07666) announced that, according to the quarterly review results of the Hang Seng Index series released by Hang Seng Indexes Company on August 21, the company has been selected and will be included in the Hang Seng Composite Index constituents, effective from September 7, 2026. The company stated that the Hang Seng Composite Index covers the top 95% of listed companies on the Hong Kong Stock Exchange by cumulative market capitalization. After being included in the Hang Seng Composite Index, the company's H-shares are expected to meet the trading eligibility for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect. The board believes that this inclusion will help broaden the shareholder base, attract long-term institutional investors, and enhance the liquidity of the shares.
METIS TECHBIO-P (07666) announced that, according to the quarterly review results of the Hang Seng Index Series released by Hang Seng Indexes Company Limited on August 21, the company has been selected and will be included in the Hang Seng Composite Index constituents, effective from September 7, 2026. The company stated that the Hang Seng Composite Index covers the top 95% of listed companies on the Hong Kong Stock Exchange by cumulative market capitalization. Following its inclusion in the Hang Seng Composite Index, the company's H shares are expected to meet the trading eligibility requirements for the Stock Connect programs between Shanghai and Hong Kong, as well as Shenzhen and Hong Kong. The board of directors believes that this inclusion will help broaden the shareholder base, attract long-term institutional investors, and enhance the liquidity of the shares.
Related Articles
Xingzheng Securities: September will be a crucial decisive window for technology, and high-quality tech assets are still expected to be the core driving force for market recovery.
Jiangsu Hengrui Pharmaceuticals (01276) experiences a shift in growth structure: acceleration of the second curve and global value release.
Zhejiang Shibao (01057) released its interim results, with a net profit attributable to shareholders of 104 million yuan, an increase of 11.48% year-on-year.
Xingzheng Securities: September will be a crucial decisive window for technology, and high-quality tech assets are still expected to be the core driving force for market recovery.
Jiangsu Hengrui Pharmaceuticals (01276) experiences a shift in growth structure: acceleration of the second curve and global value release.
Zhejiang Shibao (01057) released its interim results, with a net profit attributable to shareholders of 104 million yuan, an increase of 11.48% year-on-year.
RECOMMEND
